文献速递MDS 与骨髓增殖性肿瘤白血病

骨髓增生异常肿瘤病理诊断不一致及其对登记研究和治疗的影响

Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies.
PubMed 文献 · Blood Adv · 2023-01-01

该前瞻性观察队列研究纳入918例疑似MDS或MDS/MPN患者,比较本地临床诊断与中心裁决审查。约三分之一病例经中心审查后被重新分类,本地误诊中53%为编码错误,总体真实误诊率15%,MDS为21%。诊断不一致病例治疗率较低(25% vs 40%),7%误诊病例接受了不适当治疗。

要点

  • 918例疑似MDS或MDS/MPN患者中,约三分之一经中心审查后被重新分类。
  • 本地误诊中53%为编码错误,总体真实误诊率15%,MDS真实误诊率21%。
  • 诊断不一致病例治疗率25%,低于诊断一致病例的40%。

核心结论

  • 诊断不一致频繁发生,影响研究相关和国家登记研究的准确性,并可能导致不适当治疗。

研究设计与样本

  • 前瞻性观察队列研究,纳入918例疑似MDS或MDS/MPN患者,比较本地临床诊断与中心裁决审查。

主要发现

  • 本地诊断:264例(29%)为MDS,15例(2%)为MDS/MPN重叠,62例(7%)为ICUS,0例(0%)为AML伴<30%原始细胞,577例(63%)为其他。
  • 中心审查后:266例(29%)为MDS,45例(5%)为MDS/MPN重叠,49例(5%)为ICUS,15例(2%)为AML伴<30%原始细胞,543例(59%)为其他。
  • 本地误诊中53%为编码错误,总体真实误诊率15%,MDS真实误诊率21%。
  • 37%患者报告接受治疗,其中MDS为43%,MDS/MPN为49%,AML伴<30%原始细胞为86%。
  • 诊断不一致病例治疗率25%,低于诊断一致病例的40%;7%误诊病例接受不适当治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myelodysplastic neoplasms (MDS) are a collection of hematopoietic disorders with widely variable prognoses and treatment options. Accurate pathologic diagnoses present challenges because of interobserver variability in interpreting morphology and quantifying dysplasia. We compared local clinical site diagnoses with central, adjudicated review from 918 participants enrolled in the ongoing National Heart, Lung, and Blood Institute National MDS Natural History Study, a prospective observational cohort study of participants with suspected MDS or MDS/myeloproliferative neoplasms (MPNs). Locally, 264 (29%) were diagnosed as having MDS, 15 (2%) MDS/MPN overlap, 62 (7%) idiopathic cytopenia of undetermined significance (ICUS), 0 (0%) acute myeloid leukemia (AML) with <30% blasts, and 577 (63%) as other. Approximately one-third of cases were reclassified after central review, with 266 (29%) diagnosed as MDS, 45 (5%) MDS/MPN overlap, 49 (5%) ICUS, 15 (2%) AML with <30%, and 543 (59%) as other. Site miscoding errors accounted for more than half (53%) of the local misdiagnoses, leaving a true misdiagnosis rate of 15% overall, 21% for MDS. Therapies were reported in 37% of patients, including 43% of patients with MDS, 49% of patients with MDS/MPN, and 86% of patients with AML with <30% blasts. Treatment rates were lower (25%) in cases with true discordance in diagnosis compared with those for whom local and central diagnoses agreed (40%), and receipt of inappropriate therapy occurred in 7% of misdiagnosed cases. Discordant diagnoses were frequent, which has implications for the accuracy of study-related and national registries and can lead to inappropriate therapy. This trial was registered at www.clinicaltrials.gov as #NCT05074550.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gorak EJ, Otterstatter M, Al Baghdadi T, et al. Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies. Blood Adv. 2023. PMID: 37552083. doi:10.1182/bloodadvances.2023010061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。